**Core Concept:** Migraine prophylaxis refers to the treatment of migraines to reduce their frequency and severity. Drugs used in this context target various aspects of migraine pathophysiology, such as serotonin, calcium channels, and CGRP.

**Why the Correct Answer is Right:** The correct answer, **D**, is based on the understanding of migraine pathophysiology, specifically targeting the calcitonin gene-related peptide (CGRP) pathway. CGRP is a potent vasodilator involved in migraine triggering and perpetuation. Blocking CGRP or its receptor can effectively prevent migraine attacks.

**Why Each Wrong Option is Incorrect:**

A. **Option A (ACE Inhibitors):** Angiotensin-converting enzyme (ACE) inhibitors are primarily used in hypertension and heart failure treatment, not migraine prophylaxis. They primarily target the renin-angiotensin-aldosterone system (RAAS) and vasoconstriction.

B. **Option B (Anticonvulsants):** Anticonvulsants are primarily used in epilepsy treatment, not migraine prophylaxis. They target neuronal excitability and seizure control, not migraine-specific pathways.

C. **Option C (Antidepressants):** Antidepressants are used in psychiatric disorders and mood disorders, not migraine prophylaxis. They primarily target neurotransmitter imbalances and mood regulation rather than migraine-specific pathways.

**Clinical Pearl:** Understanding the pathophysiology of migraines is crucial when selecting appropriate prophylactic drugs. Migraine prophylaxis involves targeting specific pathways such as the CGRP pathway, not treating unrelated conditions or pathways like hypertension, epilepsy, and psychiatric disorders.

**Correct Answer:** D. Calcitonin gene-related peptide (CGRP) inhibitors (e.g., monoclonal antibodies like erenumab, galcanezumab, and fremanezumab) are a newer class of drugs specifically targeting the CGRP pathway in migraine prophylaxis, effectively preventing migraine attacks.